Aeterna Zentaris Announces Poster Presentation on Final Phase 2 Results for AEZS-108 in Endometrial Cancer at Upcoming European Society of Gynaecological Oncology Meeting

QUÉBEC CITY, July 18, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company")  today announced that final Phase 2 results in endometrial cancer on its anticancer compound, AEZS-108, will be presented during a poster session at the upcoming 17th International Meeting of the European Society of Gynaecological Oncology ("ESGO"), to be held September 11-14, 2011, at the Milan Convention Center in Milan, Italy. The trial was conducted by the German AGO Study Group and study centers in Bulgaria. AEZS-108, a targeted cytotoxic peptide conjugate, is currently in Phase 1/2 programs in prostate and bladder cancer, and has successfully completed Phase 2 trials in endometrial and ovarian cancer.

 

Abstract #247:  "AGO-GYN 5 - (Phase II) study with AEZS-108, a targeted cytotoxic LHRH analog in patients with LHRH receptor positive endometrial cancer", Wimberger P., Gorchev G., Hanker L., Stähle A., Hristamian A., Beckmann M.W., Dall P., Gründker C., Hilpert F., Sehouli J., Harter P., Taskova V., Emons G., AGO Study Group, Germany
   
Presenter:  Pauline Wimberger, MD, Gynaecology and Obstetrics, University of Duisburg-Essen, Essen, Germany
Poster Session:  Poster Shift III
Date and time:  September 14, 2011 / 7:00-8:00 am (local time)
Venue:  Milan Convention Center, Milan, Italy

About AEZS-108

AEZS-108 represents a new targeting concept in oncology using a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin. Phase 2 studies for the treatment of endometrial and ovarian cancer have been successfully completed, and Phase 1/2 trials are being conducted in prostate and bladder cancer. AEZS-108 is the first intravenous drug in a clinical study that directs the chemotherapy agent specifically to

LHRH-receptor expressing tumors, resulting in more targeted treatment with less damage to healthy tissue. AEZS-108 has been granted orphan-drug designation by the FDA and orphan medicinal product designation from the EMA for the treatment of ovarian cancer. Aeterna Zentaris owns the worldwide rights to AEZS-108.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer. The Company's innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options. For more information please visit www.aezsinc.com

 

SOURCE AETERNA ZENTARIS INC.

CONTACT:

Investor Relations

Ginette Vallieres
Investor Relations Coordinator
(418) 652-8525 ext. 265
gvallieres@aezsinc.com

Erika Moran
The Investor Relations Group
(212) 825-3210
emoran@investorrelationsgroup.com

Media Relations

Paul Burroughs
Director of Communications
(418) 652-8525 ext. 406
pburroughs@aezsinc.com

 

Posted: July 2011

View comments

Hide
(web1)